CANADA LIFE ASSURANCE Co Has $9.38 Million Stake in Insulet Co. (NASDAQ:PODD)

CANADA LIFE ASSURANCE Co raised its holdings in Insulet Co. (NASDAQ:PODD - Free Report) by 18.5% during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 35,955 shares of the medical instruments supplier's stock after buying an additional 5,626 shares during the quarter. CANADA LIFE ASSURANCE Co owned 0.05% of Insulet worth $9,378,000 at the end of the most recent quarter.

A number of other large investors also recently modified their holdings of the business. SBI Securities Co. Ltd. bought a new position in Insulet during the fourth quarter worth $36,000. SRS Capital Advisors Inc. increased its holdings in shares of Insulet by 43.1% during the 4th quarter. SRS Capital Advisors Inc. now owns 186 shares of the medical instruments supplier's stock worth $49,000 after purchasing an additional 56 shares during the period. Friedenthal Financial acquired a new position in shares of Insulet during the fourth quarter valued at about $57,000. Assetmark Inc. lifted its stake in shares of Insulet by 1,447.1% in the fourth quarter. Assetmark Inc. now owns 263 shares of the medical instruments supplier's stock valued at $69,000 after buying an additional 246 shares during the period. Finally, Blue Trust Inc. grew its position in Insulet by 117.3% during the fourth quarter. Blue Trust Inc. now owns 276 shares of the medical instruments supplier's stock worth $72,000 after buying an additional 149 shares in the last quarter.

Analyst Upgrades and Downgrades

PODD has been the topic of several recent research reports. Raymond James reissued an "outperform" rating and set a $328.00 price objective (up previously from $294.00) on shares of Insulet in a report on Friday, February 21st. TD Cowen boosted their price target on shares of Insulet from $264.00 to $324.00 and gave the company a "buy" rating in a report on Friday, January 3rd. StockNews.com downgraded shares of Insulet from a "buy" rating to a "hold" rating in a report on Tuesday, March 4th. Royal Bank of Canada started coverage on shares of Insulet in a research note on Thursday, March 6th. They set an "outperform" rating and a $340.00 price target for the company. Finally, Citigroup upped their price objective on Insulet from $310.00 to $355.00 and gave the company a "buy" rating in a research note on Friday, February 21st. Four investment analysts have rated the stock with a hold rating and fourteen have issued a buy rating to the company. According to data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average target price of $292.06.

Insulet Price Performance

Shares of Insulet stock traded up $1.33 during midday trading on Friday, reaching $260.71. The company had a trading volume of 465,388 shares, compared to its average volume of 713,786. The company has a current ratio of 3.68, a quick ratio of 2.80 and a debt-to-equity ratio of 1.21. The stock has a fifty day simple moving average of $260.21 and a 200 day simple moving average of $261.91. Insulet Co. has a 1-year low of $160.19 and a 1-year high of $289.46. The company has a market capitalization of $18.31 billion, a price-to-earnings ratio of 45.03, a price-to-earnings-growth ratio of 3.62 and a beta of 1.30.

Insulet (NASDAQ:PODD - Get Free Report) last released its earnings results on Thursday, February 20th. The medical instruments supplier reported $1.15 EPS for the quarter, beating the consensus estimate of $1.00 by $0.15. Insulet had a return on equity of 24.46% and a net margin of 20.19%. The company had revenue of $597.50 million during the quarter, compared to analysts' expectations of $582.02 million. As a group, equities research analysts forecast that Insulet Co. will post 3.92 earnings per share for the current year.

Insider Buying and Selling at Insulet

In other news, Director Wayne A.I. Frederick sold 1,825 shares of the business's stock in a transaction dated Tuesday, March 25th. The stock was sold at an average price of $275.00, for a total transaction of $501,875.00. Following the completion of the transaction, the director now directly owns 3,231 shares in the company, valued at approximately $888,525. The trade was a 36.10 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Corporate insiders own 0.47% of the company's stock.

Insulet Company Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.